Furthermore, genetic ablation of Hck or treatment with an Hck-selective small molecule inhibitor reduced tumor growth in mouse models of colon and gastric cancers [146, 147], and when combined with anti-PD1 augmented anti-tumor immune responses [52]. This evidence concerns the gene HCK and gastric cancer.